mRNA specalist Ethris raises $26m in Series B financingGerman mRNA and LNP specialist Ethris GmbH has closed a $26m Series B round led by Laureus Capital. more ➔
Evotec and Boehringer Ingelheim enter drug discovery deal Evotec SE will use its PanOmics platform to validate and screen targets and drug candidates in ophtalmology for Boehringer Ingelheim. more ➔
BioNTech and Pfizer evaluate Omicron-specific vaccinePfizer Inc and BioNTech SE have started clinical safety testing of an Omikron-specific vaccine in healthy adults 18 through 55 years of age. more ➔
Cytovation AS kicks-off with $20m Series A financingNorway’s immuno-oncology specialist Cytovation A/S has raised $20m in a Series A financing led by early-stage investor Sandwater. more ➔
Valneva vaccine neutralises Omicron variantFrench-Austrian vaccine specialist Valneva SE has demonstrated that its COVID-19 vaccine induced neutralisation of 87% of the Omicron variant. more ➔
Neurimmune expands drug discovery collaboration with Ono PharmaceuticalSwiss Neurimmune AG has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. covering antibody drug targeting neurodegenerative diseases more ➔
Evotec and Lilly to collaborate in metabolic diseasesGerman Evotec SE has entered into a US$1bn drug discovery and development partnership with Eli Lilly and Company in the field of metabolic and renal diseases and diabetes. more ➔
Protagen, BioAnalytix and GeneWerk launch ProtaGeneFollowing their last year announcement to merge, Protagen Protein Services GmbH, BioAnalytix, Inc., and GeneWerk GmbH launch a CRO named ProtaGene. more ➔
BioNTech SE licences Cresendo Bio’s Humabody technologyBioNTech and Crescendo Biologics have signed a US-$790m deal to develop multi-specific precision immunotherapies . more ➔
Novartis AG executes licence option with Molecular PartnersAfter Molecular Partners AG reported an 78% reduction of hospitalisation by a single ensovibep dose in infected COVID-19 patients, Novartis AG is to pay a CHF150m milestone. more ➔
